Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group Income Statement

Financials in millions GBP. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	10	0	45.58	0	0	0	0	0
Cost of Revenue	2.57	-1.15	22.39	0	0	0	0	0
Gross Profit	7.43	1.15	23.2	0	0	0	0	0
Selling, General & Admin	18.42	26.11	19.92	26.53	19.89	14.72	13.37	14.52
Research & Development	17.42	29.47	29.45	20.43	29.51	28.38	43.26	30.7
Other Operating Expenses	0	0	-0.14	13.59	0	0	0	0
Operating Expenses	35.84	55.57	49.22	60.55	49.4	43.1	56.63	45.22
Operating Income	-28.42	-54.43	-26.03	-60.55	-49.4	-43.1	-56.63	-45.22
Interest Expense / Income	2.88	4.18	5.03	7.98	5.46	4.76	1.36	0.22
Other Expense / Income	-0.02	-13.94	-48.86	139.53	-3.46	-1.22	0.7	-3.3
Pretax Income	-31.28	-44.67	17.8	-208.06	-51.4	-46.63	-58.69	-42.15
Income Tax	-1.81	-2.45	1.9	-3.53	-7.84	-6.6	-10.19	-6.66
Net Income	-29.47	-42.22	15.91	-204.54	-43.56	-40.04	-48.5	-35.49
Shares Outstanding (Basic)	659	603	545	339	71	87	87	-
Shares Outstanding (Diluted)	659	603	-	-	-	-	-	-
Shares Change	9.33%	10.78%	60.76%	376.09%	-18.21%	-	-	-
EPS (Basic)	-0.20	-0.35	0.13	-3.00	-2.44	-2.81	-3.50	-3.94
EPS (Diluted)	-0.20	-0.35	-0.31	-3.00	-2.44	-2.81	-3.50	-3.94
Free Cash Flow	-21.13	-48.83	-7.22	-35.45	-57.44	-28.97	-40.21	-37.08
Free Cash Flow Per Share	-0.16	-0.41	-0.07	-0.52	-4.04	-1.67	-2.31	-
Gross Margin	74.26%	-	50.89%	-	-	-	-	-
Operating Margin	-284.16%	-	-57.11%	-	-	-	-	-
Profit Margin	-294.66%	-	34.90%	-	-	-	-	-
Free Cash Flow Margin	-211.32%	-	-15.83%	-	-	-	-	-
Effective Tax Rate	-	-	10.65%	-	-	-	-	-
EBITDA	-27.34	-39.6	23.63	-198.09	-43.96	-41.83	-57.28	-41.89
EBITDA Margin	-273.36%	-	51.85%	-	-	-	-	-
Depreciation & Amortization	1.06	0.89	0.8	2	1.97	0.05	0.05	0.04
EBIT	-28.4	-40.49	22.83	-200.08	-45.93	-41.87	-57.33	-41.93
EBIT Margin	-283.97%	-	50.09%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).